Sedation and Hemodynamic Control During ECMO: The Perfusionist’s Role

Introduction

Extracorporeal Membrane Oxygenation (ECMO) is a life-saving intervention for patients with severe cardiac and/or respiratory failure. Unlike cardiopulmonary bypass (CPB), ECMO can run for days to weeks, requiring meticulous sedation and hemodynamic management to optimize patient outcomes. Perfusionists play a crucial role in adjusting flows, monitoring drug interactions, and ensuring stable perfusion.

Sedation Strategies in ECMO Patients

Sedation in ECMO patients is required for comfort, ventilator synchrony, and prevention of agitation, which can cause cannula displacement or hemodynamic instability. However, drug pharmacokinetics are altered in ECMO due to increased volume of distribution (Vd) and drug sequestration in the circuit (Shekar et al., 2012).

Commonly Used Sedatives and Analgesics

1. Midazolam (Benzodiazepine).

• Used for: Continuous sedation and anxiolysis.
• Dose: 0.02–0.1 mg/kg/hr IV infusion.
• Caution: Prolonged sedation due to hepatic metabolism impairment in critically ill patients (Barr et al., 2013).

2. Propofol (Short-acting Sedative)

• Used for: Short-term sedation and neurological assessments.
• Dose: 5–50 mcg/kg/min IV infusion.
• Issue in ECMO: High sequestration in ECMO circuits due to lipophilic nature (Shekar et al., 2015).
• Risk: Propofol Infusion Syndrome (PRIS) in prolonged use (Liu et al., 2020).

3. Dexmedetomidine (Alpha-2 Agonist)

• Used for: Sedation without respiratory depression, beneficial in ECMO weaning.
• Dose: 0.2–1.5 mcg/kg/hr IV infusion.
• Advantage: Facilitates spontaneous breathing, reducing ventilator dependence (Shehabi et al., 2013).

4. Opioids (Fentanyl, Morphine)

• Used for: Analgesia and sedation.
• Fentanyl Dose: 1–5 mcg/kg/hr IV infusion.
• Morphine Dose: 0.05–0.1 mg/kg IV every 2–4 hours.
• ECMO Consideration: High circuit sequestration of fentanyl requires dose adjustments (Mulla et al., 2021).

5. Ketamine (NMDA Antagonist)

• Used for: Sedation and analgesia in hemodynamically unstable patients.
• Dose: 0.5–2 mg/kg IV bolus, followed by 0.2–0.75 mg/kg/hr infusion.
• Advantage: Maintains cardiovascular stability (Tanaka et al., 2022).

Hemodynamic Control During ECMO

ECMO significantly alters cardiovascular physiology, necessitating careful titration of vasoactive and inotropic agents to maintain perfusion. Management strategies differ between VA-ECMO (cardiac support) and VV-ECMO (respiratory support).

Key Drugs for Hemodynamic Support

1. Vasopressors (Increase Blood Pressure)

• Neo-Synephrine (Phenylephrine) – Pure alpha-agonist, used for vasoplegia. Dose: 0.5–6 mcg/kg/min IV infusion.
• Noradrenaline (Norepinephrine) – First-line for hypotension in VA-ECMO. Dose: 0.01–0.5 mcg/kg/min IV (Levy et al., 2020).
• Vasopressin – For refractory hypotension. Dose: 0.03–0.04 units/min IV (Harhay et al., 2019)

2. Inotropes (Improve Cardiac Output in VA-ECMO)

• Adrenaline (Epinephrine) – Beta-agonist, increases heart contractility. Dose: 0.01–0.5 mcg/kg/min IV infusion.
• Dobutamine – Improves cardiac output without vasoconstriction. Dose: 2–20 mcg/kg/min IV infusion (MacLaren et al., 2022).

3. Vasodilators (Reduce Afterload)

• Nitroglycerin – Used in VA-ECMO to reduce afterload and improve ventricular unloading. Dose: 5–200 mcg/min IV infusion.
• Milrinone – Inodilator, enhances cardiac output while reducing afterload. Dose: 0.375–0.75 mcg/kg/min IV infusion (Delle Karth et al., 2018).

Perfusionist’s Role in Sedation and Hemodynamic Management

1. Monitoring Drug Sequestration in ECMO Circuits

• Lipophilic drugs (Propofol, Fentanyl) may bind to the ECMO circuit, requiring higher doses to achieve the desired effect (Shekar et al., 2012).

2. Optimizing Flows and Perfusion

• Adjusting ECMO flows to maintain adequate oxygen delivery (DO₂) while preventing excessive afterload (VA-ECMO).

3. Balancing Sedation with Neurological Monitoring

• Avoiding deep sedation when neurological assessment is required (e.g., post-cardiac arrest, stroke risk).
• Using Dexmedetomidine or intermittent sedation holidays (Shehabi et al., 2013).

4. Preventing Hypotension and Vasoplegia

• Close monitoring of systemic vascular resistance (SVR), ensuring adequate MAP (Mean Arterial Pressure) for organ perfusion.
• Adjusting vasopressors/inotropes based on patient response.

Conclusion

Sedation and hemodynamic control during ECMO require a multidisciplinary approach involving intensivists, perfusionists, and critical care teams. Understanding drug interactions, adjusting doses based on ECMO physiology, and maintaining optimal perfusion are crucial for patient survival. Perfusionists play a vital role in ensuring that sedation and hemodynamic strategies align with ECMO objectives, improving patient outcomes.

References

• Barr, J., et al. (2013). «Clinical practice guidelines for the management of pain, agitation, and delirium in adult ICU patients.» Critical Care Medicine, 41(1), 263–306.
• Delle Karth, G., et al. (2018). «Milrinone in ECMO patients: Hemodynamic benefits and risks.» European Journal of Heart Failure, 20(4), 713–720.
• Harhay, M.O., et al. (2019). «Vasopressin in refractory hypotension during ECMO support.» JAMA Cardiology, 4(10), 875–883.
• Levy, B., et al. (2020). «Vasoactive agents in ECMO patients: A critical review.» Critical Care, 24, 650.
• Shehabi, Y., et al. (2013). «Early sedation and mortality in critically ill patients.» American Journal of Respiratory and Critical Care Medicine, 188(7), 841–846.
• Shekar, K., et al. (2012). «Sequestration of drugs in ECMO circuits: Implications for dosing.» Critical Care Medicine, 40(7), 2222–2232.